Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + Cadonilimab with Chemotherapy in Extensive-stage Small Cell Lung Cancer
ChiCTR2400091458Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab and cadonilimab in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 6-month progression-free survival rate. Started Oct 2024; status: recruiting.
02
Drugs
ivonescimabcadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400091458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091458.